Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Director departure
Inv. presentation
Appointed director

Diadexus, Inc. (DDXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2018 SC 13G/A MORGAN STANLEY reports a 0% stake in Diadexus, Inc.
02/13/2018 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2017 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/29/2016 10-Q Quarterly Report for the period ended March 31, 2016
04/28/2016 8-K Quarterly results
04/18/2016 8-K Form 8-K - Current report
04/01/2016 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
03/29/2016 10-K Annual Report for the period ended December 31, 2015
03/28/2016 8-K Quarterly results
Docs: "Press Release entitled “Updated - Diadexus, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results.”"
03/17/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/30/2015 10-Q Quarterly Report for the period ended September 30, 2015
10/26/2015 8-K Quarterly results
Docs: "PLAC ® ELISA o Signed an exclusive, license and supply agreement granting OriGene rights to develop and commercialize Diadexus' proprietary PLAC ® ELISA in certain Asian countries . Diadexus will supply to OriGene the raw materials and reagents necessary to assemble, develop, produce, seek marketing authorization for, and sell PLAC ® ELISA in the Territory. Upon commencement of commercial sales, Diadexus is eligible to receive sales-based milestones as well as mid-single-digit royalties on net sales. 3 ● PLAC ® Activity o A new partnership established with Mayo Clinic for the integration and use of PLAC ® Activity testing into clinical practice. The parties recently completed a successful kick-off meeting with key sales and marketing personnel. Once fully integrated, the test will be..."
09/08/2015 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
08/20/2015 8-K Regulation FD Disclosure
08/13/2015 10-Q Quarterly Report for the period ended June 30, 2015
08/13/2015 8-K Quarterly results
Docs: "Diadexus, Inc. Reports Second Quarter 2015 Financial Results",
"Diadexus, Inc. Reports Second Quarter 2015 Financial Results"
07/16/2015 4 Form 4 - Statement of changes in beneficial ownership of securities
07/16/2015 4 Sperzel John J III (Director) has filed a Form 4 on Diadexus, Inc.
Txns: Granted 4,000 options to buy @ $4.21, valued at $16.8k
07/16/2015 4 SULAT JAMES R (Director) has filed a Form 4 on Diadexus, Inc.
Txns: Granted 4,000 options to buy @ $4.21, valued at $16.8k
07/16/2015 4 Hutt Pollard Elizabeth Ann (Director) has filed a Form 4 on Diadexus, Inc.
Txns: Granted 4,000 options to buy @ $4.21, valued at $16.8k
07/16/2015 4 Drexler Karen (Director) has filed a Form 4 on Diadexus, Inc.
07/02/2015 4 RAFIELD LORI F PHD (CEO) has filed a Form 4 on Diadexus, Inc.
07/02/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/01/2015 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Diadexus, Inc"
06/10/2015 8-K Submission of Matters to a Vote of Security Holders
05/13/2015 10-Q Quarterly Report for the period ended March 31, 2015
05/12/2015 8-K Quarterly results
Docs: "Diadexus, Inc. Reports First Quarter 2015 Financial Results"
04/30/2015 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/30/2015 DEF 14A Form DEF 14A - Other definitive proxy statements
04/22/2015 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Lori Rafield, Ph.D. Appointed Permanent CEO of Diadexus SOUTH SAN FRANCISCO, Calif., April 20, 2015 -- Diadexus, Inc. , a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced the appointment of Lori F. Rafield, Ph.D. as chief executive officer of the Company on a permanent basis, effective immediately. Dr. Rafield has continued to serve as chairman since 2010. She assumed the responsibility of interim executive chair in June 2014 and then was appointed interim chief executive officer in January 2015. “Lori has assembled a leadership team with deep operating experience and we are pleased she has agreed to lead this team as Diadexus' permanent chief executive officer,” said Karen Drexler, independent director of the b..."
04/21/2015 4 RAFIELD LORI F PHD (Interim CEO) has filed a Form 4 on diaDexus, Inc.
04/17/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement, by and among diaDexus, Inc., Leap Tide Capital Management, LLC and Jan Loeb"
03/31/2015 4 Hutt Pollard Elizabeth Ann (Director) has filed a Form 4 on diaDexus, Inc.
Txns: Granted 30,000 options to buy @ $0.44, valued at $13.2k
03/30/2015 4 RAFIELD LORI F PHD (Interim CEO) has filed a Form 4 on diaDexus, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy